The US Department of Health and Human Services has updated its adult antiretroviral treatment guidelines. The following changes have been made to antiretroviral regimens recommended for treatment of HIV-1 infection in antiretroviral naïve patients:
- Fosamprenavir and ritonavir-boosted fosamprenavir are added as part of alternative PI-based regimens for initiation of therapy in treatment-naïve patients.
Ritonavir-boosted amprenavir has been removed as an alternative PI-based regimen for initiation of therapy in treatment-naïve patients.
Indinavir (unboosted) has been removed as an alternative PI-based regimen for initiation of therapy in treatment-naïve patients. A new table of Antiretroviral dosing recommendations for patients with renal or hepatic dysfunction has been created.New safety information regarding the risks of nevirapine-associated symptomatic hepatic events has been added to the text of the guidelines and drug interaction information for fosamprenavir has also been added.
Click here to view the updated guidelines.
Further information on this website
US treatment guidelines updated - November 2003 news story
US HIV guidelines: choose either lopinavir or efavirenz in first-line treatment - July 2003 new story